SpyGlass Pharma (SGP) Q3 2026 earnings — TrendMatrix coverage

Adjusted EPS

-$0.73

Estimate

-$0.64

Surprise

-13.9%

Score today

4.8/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

SpyGlass Pharma (SGP) reported a wider loss than forecast — adjusted EPS of -$0.73 against the -$0.64 estimate (a 13.9% shortfall).

• SpyGlass Pharma Reports Third Quarter 2026 Financial Results and Corporate Updates — fiscal.ai, 2026-11-11
• SpyGlass Pharma Q3 EPS $(0.73) Misses $(0.63) Estimate — benzinga, 2026-11-11

TrendMatrix currently rates SGP Sell at 4.8/10; no pre/post engine snapshot brackets this report.

0 of the last 3 quarters beat the estimate; this quarter's -13.9% surprise compares with a -37.8% four-quarter average.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$34.97

Price target

$38.28

Stop

$32.52

Upside to target

+9.5%

Reward-to-risk

0.6:1

Model outputs from TrendMatrix’s engine as of 2026-11-12 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$1.17B

P/E (fwd)

-12.4

52-week range

$17.06–$39.92

Off 52-week high

12.4%

RSI (14)

70

Volume vs avg

0.67×

Score today

4.8/10